Sigyn Therapeutics (OTCMKTS:SIGY) Issues Quarterly Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) posted its earnings results on Tuesday. The company reported ($0.42) earnings per share (EPS) for the quarter, Zacks reports.

Sigyn Therapeutics Stock Performance

Shares of Sigyn Therapeutics stock remained flat at $3.53 during trading on Tuesday. The business’s 50-day moving average is $3.92 and its two-hundred day moving average is $4.03. The stock has a market cap of $5.67 million, a PE ratio of -0.74 and a beta of -1.04. Sigyn Therapeutics has a 1 year low of $3.15 and a 1 year high of $6.34.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.